JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is a phase II, open, single-center clinical study to evaluate the efficacy and safety of
JS001 combined with Axitinib in the treatment of advanced non-small cell lung cancer without
activated EGFR mutation, ALK fusion and ROS fusion after or during first-line chemotherapy.
About 50 subjects will be included in this study and will be treated with JS001 combined with
acitinib. Each cycle is 21 days.